Factors Influencing the Acceptance of a Novel Diagnostic Technology in the Coverage Policy of a Health Care Plan: Case Study
Mark D. Hiatt, MD, MBA, MS, Vice President, Medical Affairs, Guardant Health; Eugean Jiwanmall, MBA, MPH
Senior Research Analyst, Medical Policy & Technology Evaluation, Independence Blue Cross
This study of one plan’s evaluation and ultimate acceptance of liquid biopsy, in the context of ascertaining the genomic drivers of lung cancer, will illustrate the factors influencing such coverage decisions. Factors discussed include (a) published studies in support of the technology, (b) the description of the technology, and (c) the opinion of other plans and their intermediaries.